Initial uptake in use of sildenafil in general practice

Prior research has shown that sildenafil is a widely prescribed treatment for erectile dysfunction. It was already known that sildenafil interacts with nitrates and certain other medications. No prior work had resolved the extent of sildenafil use in general practice settings. This gap motivated an analysis of prescription data to better understand uptake patterns. The prevalence of erectile dysfunction in older male populations was already established at around 10%. That uncertainty drove the need to assess co-prescribing practices in real-world settings. No prior work had examined the relationship between sildenafil and drug-related impotence. This uncertainty highlights the importance of analyzing prescription data for safety and cost implications.

The aim of this study was to evaluate the initial uptake of sildenafil in general practice. Researchers focused on prescription data from a specific region in Ireland. The study sought to determine co-prescribing patterns with medications that could interact with sildenafil. The motivation for this work was to assess the safety and cost-effectiveness of sildenafil use. The researchers examined a population of over 334,000 individuals. The study period spanned six months, from July to December 1999. The goal was to identify how many patients received sildenafil and what other medications they were prescribed. The study also aimed to assess the proportion of patients who might be at risk due to drug interactions.

The researchers analyzed prescription data from the Eastern Health Board Region in Ireland. They focused on data from the General Medical Services program covering primary care. The study population included individuals over 16 years of age who might experience erectile dysfunction. The team identified patients who received sildenafil prescriptions during the six-month period. They calculated the proportion of patients who were also prescribed nitrates or other interacting drugs. The study examined the cost of sildenafil prescriptions relative to the annual drug budget. Researchers also assessed medications known to be associated with impotence. The analysis included both prescription frequency and drug interactions.

A total of 1422 patients received 3740 prescriptions for sildenafil during the study period. These patients represented 1.4% of the male population over 16 years of age in the region. The cost of sildenafil prescriptions accounted for 0.14% of the annual drug budget. Up to 2.5% of patients were co-prescribed nitrate therapy. Approximately 6% of patients received medications that could interact with sildenafil. Around 25% of patients were prescribed drugs associated with impotence. The uptake of sildenafil was lower than anticipated based on prevalence estimates. The study found a low rate of co-prescribing with potentially interacting medications.

The authors suggest that the initial uptake of sildenafil was lower than expected in general practice. They propose that the cost of sildenafil prescriptions was relatively low compared to the drug budget. The study found a low rate of co-prescribing with nitrates and other interacting drugs. The researchers suggest that medication use may contribute to erectile dysfunction in some patients. The findings indicate that sildenafil is being used cautiously in primary care. The low rate of co-prescribing suggests a degree of awareness among prescribers. The study does not suggest widespread misuse or overuse of sildenafil. The authors propose that further monitoring of prescribing patterns may be useful.